Browsing Category
Medicine
CME on Head Injury Management Held at Amrita Hospital, Faridabad
FARIDABAD : It is important to increase awareness about prevention of head injuries among people as it is the main cause of death in accidents, with India known as the head injuries capital of the world due to high number of road…
Middle Eastern woman with gigantic breasts undergoes surgery at Amrita Hospital, Faridabad
FARIDABAD : A 23-year-old woman from Middle East, in the prime of her youth, was in great distress because of her giant breast size which was induced due to her pregnancy. Due to a rare condition, her breasts had grown extremely…
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately!-->…
Bharat Biotech’s nasal vaccine ‘iNCOVACC’ to be available at Rs 325 for govt…
Bharat Biotech has said that its nasal vaccine against Covid-19, iNCOVACC, would be available to the public from the fourth week of January. The Hyderabad-based biotechnology company said that the vaccine will cost 800 rupees for private…
Pfizer: U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or!-->…
Pfizer: Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg!-->…
Pfizer: Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
Pfizer Inc. (NYSE:PFE) today announced 10.4 month follow-up data from the pivotal Phase 2 MagnetisMM-3 clinical trial suggesting elranatamab, a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), is efficacious and!-->…
Pfizer: Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative…
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC).!-->…
Pfizer: Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for…
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today reported antibody persistence data six months after the completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule with their!-->…
World’s first intra-nasal vaccine for COVID gets CDSCO approval for restricted use in emergency…
The world’s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation for restricted use in emergency situations in the age group of 18 and above. Union Minister Dr Jitendra…